Millipore Expands Collection of Lipid Kinases
22 Nov 2007Millipore Corporation, a Life Science leader providing technologies, tools and services for the bioscience research and biopharmaceutical manufacturing industry, today announced the expansion of its PI3 kinase line, making it the broadest panel of lipid kinases available worldwide. Millipore now offers 17 lipid kinases, available both for purchase and as part of its gold-standard KinaseProfiler™ service. No other company provides this many kinases.
Lipid kinases are one of the most promising new classes of potential drug targets. PI3 kinases regulate a wide variety of cellular functions, including cell growth, proliferation, differentiation, motility, survival, and intracellular trafficking. As a result, defects in PI3 kinase function lead to multiple disease states, including several forms of cancer. Millipore’s newly-expanded lipid kinase panel and KinaseProfiler service provide the tools to dissect the networks underlying PI3 kinase signaling, essential to the design of new therapies.
Combined with Millipore’s industry-leading PI3 Kinase HTRF™ Assay, KinaseProfiler service, and small-molecule inhibitors, the expanded lipid kinase panel provides researchers with the most complete solution to studying lipid kinase signaling. The new lipid kinase panel includes both wild type and disease-linked mutants.